<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04743518</url>
  </required_header>
  <id_info>
    <org_study_id>PI2020_843_0114</org_study_id>
    <nct_id>NCT04743518</nct_id>
  </id_info>
  <brief_title>Impact of Anti-TNF, Vedolizumab and Tofacitinib on Aortic Stiffness, Carotid Intima-media Thickness and Cardiovascular Risk of Patients With Ulcerative Colitis</brief_title>
  <acronym>VASC-UC</acronym>
  <official_title>Impact of Anti-TNF, Vedolizumab and Tofacitinib on Aortic Stiffness, Carotid Intima-media Thickness and Cardiovascular Risk of Patients With Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An increased risk of cardiovascular (CV) diseases has been observed in patients with&#xD;
      inflammatory bowel diseases (IBD). The impact of IBD drugs, such as anti-TNF, anti-integrins&#xD;
      or anti-JAK, on the risk of CV events in IBD is remains unknown. Aortic pulse wave velocity&#xD;
      (aPWV), a measure of aortic stiffness, and carotid intima media thickness (CIMT) are both&#xD;
      predictors of cardiovascular events and are increased in patients with IBD. The investigators&#xD;
      aimed to prospectively compare the CV risk, CIMT, arterial stiffness and biomarkers of&#xD;
      endothelial dysfunction at baseline and after 3 and 12 months of anti-TNF, vedolizumab and&#xD;
      tofacitinib.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2, 2021</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>variation of carotid intima media thickness (CIMT) between the 3 patient groups</measure>
    <time_frame>at the end of month 3</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>anti-TNF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>vedolizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>tofacitinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Aortic pulse wave velocity</intervention_name>
    <description>Aortic pulse wave velocity (aPWV) is a measure of aortic stiffness</description>
    <arm_group_label>anti-TNF</arm_group_label>
    <arm_group_label>tofacitinib</arm_group_label>
    <arm_group_label>vedolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>carotid intima media thickness (CIMT)</intervention_name>
    <description>carotid intima media thickness (CIMT)</description>
    <arm_group_label>anti-TNF</arm_group_label>
    <arm_group_label>tofacitinib</arm_group_label>
    <arm_group_label>vedolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ulcerative colitis evolving for at least 6 months,&#xD;
&#xD;
          -  Patient older than 18 years,&#xD;
&#xD;
          -  Initiating a treatment by infliximab, adalimumab, golimumab, vedolizumab or&#xD;
             tofacitinib,&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with anti-hypertensive, antiplatelet or lipid-lowering drugs without stable&#xD;
             dosage within the 3 months before the study and over the study period,&#xD;
&#xD;
          -  Patients with a cardiovascular event such as myocardial infarction and stroke,&#xD;
&#xD;
          -  Diabetic patient,&#xD;
&#xD;
          -  Pregnant women,&#xD;
&#xD;
          -  Minor&#xD;
&#xD;
          -  people unable to give their consent to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mathurin Fumery, Pr</last_name>
    <phone>03 22 08 88 51</phone>
    <email>Fumery.mathurin@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathurin Fumery, Pr</last_name>
      <phone>03 22 08 88 51</phone>
      <email>Fumery.mathurin@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Antoinette Sevestre, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 3, 2021</study_first_submitted>
  <study_first_submitted_qc>February 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2021</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ulcerative colitis</keyword>
  <keyword>cardiovascular risk</keyword>
  <keyword>CIMT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

